TAS-115 mesylate is primarily utilized in the field of oncology due to its role as a multi-kinase inhibitor. It targets specific kinases involved in cancer cell proliferation and survival, making it a potential therapeutic agent for various types of cancers. Its application is particularly significant in inhibiting tumor growth and metastasis by blocking key signaling pathways that drive cancer progression. Additionally, TAS-115 mesylate is being investigated for its ability to enhance the efficacy of other cancer treatments, such as chemotherapy and radiation therapy, by sensitizing cancer cells to these modalities. Research is ongoing to explore its potential in treating solid tumors and hematologic malignancies, with a focus on improving patient outcomes and reducing treatment-related side effects.